GUYLE DONHAM: Open Payments
NPI 1659386001 · COMANCHE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$900 in 50 payments from 18 companies in 2025. Trend: 2023 $1,830 · 2024 $1,380 · 2025 $900
Food & beverage: $900
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 15 | $239 |
| Otsuka America Pharmaceutical, Inc. | 8 | $136 |
| Lilly USA, LLC | 5 | $88 |
| Astellas Pharma US Inc | 2 | $52 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $52 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $43 |
| Supernus Pharmaceuticals, Inc. | 2 | $39 |
| ANI Pharmaceuticals, Inc. | 1 | $32 |
| ABBVIE INC. | 2 | $30 |
| Abbott Laboratories | 2 | $29 |
Products named: KRYSTEXXA, REXULTI, MOUNJARO, Veozah, Kerendia, EVENITY, JOURNAVX, Qelbree.
Industry payments across TX — which companies pay providers there.
